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Implantation of amniotic membrane as a vascular
substitute in the external jugular vein of juvenile
sheep
Habibollah Peirovi, MD,a Navid Rezvani, MD,a Mostafa Hajinasrollah, DVM,b
Seied Sajjad Mohammadi, MD,a and Hassan Niknejad, PharmD, PhD,a Tehran, Iran
Objective: Amniotic membrane, as a natural biomaterial, has many advantages, such as low immunogenicity, anti-
inflammation, antifibrosis, and rich extracellular matrix components, which make it a promising source for vascular tissue
engineering. This study assessed the feasibility of constructing a vein conduit from the amniotic membrane and
implanting it in the external jugular vein of juvenile sheep.
Methods:Human amniotic membrane was prepared using fresh human placenta. For construction of a tube such as a vein,
the membrane was rolled around a tube and amniotic membrane-constructed conduits were interposed to the external
jugular vein by end-to-end anastomosis. Grafts were assessed for patency at weeks 5 and 48 and explanted for evaluation
with histologic and microscopic techniques.
Results: At 5 weeks after implantation, the grafts were completely patent and displayed no signs of dilation. The internal
surface was smooth and shiny, without any evidence of thrombus formation. After 48 weeks, grafts were still completely
patent and displayed no signs of intimal thickening, dilation, or stenosis. No inflammation or fibrosis was evident.
Histologic evaluation of the explanted grafts demonstrated a monolayer of endothelial cells. Scanning electron
microscopy revealed a confluent layer of cells with normal endothelial cell morphology. A monolayer of cells positive for
von Willebrand factor was detected in histology sections.
Conclusions: The findings of this study confirm that the amniotic membrane can be a proper substitute for vascular tissue
engineering. (J Vasc Surg 2012;56:1098-104.)
Clinical Relevance: Amniotic membrane is a natural biomaterial that has successfully been used in different fields of
surgery. This research evaluated conduit constructed from amniotic membrane as a substitute conduit in the external
jugular vein in an animal model. The promising results of this study showed that the amniotic membrane might evolve
into a clinically useful alternative for patients lacking vein for vascular reconstructions.
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aMany approaches have been taken to replace diseased
or damaged blood vessels. Autologous graft remains the
best choice for this purpose. However, many patients un-
dergo bypass with allografts or prosthetic grafts because of
poor quality of veins or unavailability of a suitable vessel.
Allogenic grafts demonstrate long-term patency and reac-
tivity, but their clinical use is prevented by high immuno-
genicity.1 Prosthetic materials, such as woven polyethylene
terephthalate (Dacron) and expanded polytetrafluoroeth-
ylene are other alternatives for vascular grafts. However,
these substitutes are unable to grow and remodel or are
prone tomaterial-related complications, including stenosis,
thrombosis, calcification, and infection.2,3
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1098A potential solution to intrinsic thrombogenicity after
rosthetic graft implantations is modifying of the graft
urface by seeding of endothelial cells.2 Although, seeding
f endothelial cells on synthetic grafts can significantly
mprove graft performance in animals, this process does not
ompletely eliminate thrombogenesis and is associated with
ther problems, such as neointimal hyperplasia, possibly
esulting from the lack of a confluent layer of endothelial
ells on the graft lumen.4 For these reasons the search for
mproved vascular substitutes remains unchallenged.
Amniotic membrane (AM) is the innermost membrane
ining the placenta facing the fetus. This membrane consists
f a simple cuboidal epithelium, a thick basement mem-
rane, and an avascular mesenchymal stroma.5 A variety of
haracteristics make the AM suitable for using in vascular
issue engineering. The thick basement membrane of AM is
omposed of collagen types III, IV, and V and noncollag-
nous glycoproteins, including laminin, nidogen, and fi-
ronectin.5 The basement membrane of the AM is a proper
ubstrate for seeding and growth of many types of cells,
mong them epithelial progenitor and endothelial cells.5,6
ompared with synthetic materials, this feature is an advan-
age for the AM to be used as a scaffold for tissue engineer-
ng, because the AM has no need to be coated with an
dhesive and natively supports cell adhesion. It is notewor-
hy that researchers have examined various adhesive coat-
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Volume 56, Number 4 Peirovi et al 1099ings, including collagen, laminin, and fibronectin, on syn-
thetic materials to improve cell adhesion to the graft and
long-term performance of cell-seeded grafts.4
In addition, the AM is an immune-privileged tissue that
rarely causes immunologic rejection.5 The amniotic epithe-
lium produces potent natural antimicrobial and anti-
inflammatory agents that may help protect the graft from
infection.5,7 Therefore, the AM serves as a scaffold that has
appropriate structural and functional properties andmay be
a superior alternative to synthetic grafts.
The aim of this research was to investigate the AM as a
substitute for vein graft and to evaluate patency and histo-
logic changes of AM constructed conduit (AMCC) in an
animal model.
METHODS
Preparation of AM. AM was prepared using eight
fresh human placentas. Informed consent was obtained
from each donor. All procedures were performed under
sterile conditions. The placentas were obtained immedi-
ately after elective cesarean sections with normal gestation.
Those that were accepted after serologic screening for
human immunodeficiency virus, human hepatitis type B
and C, and syphilis were immersed in phosphate-buffered
saline (PBS, Sigma, St. Louis, Mo) containing penicillin
(50 g/mL), streptomycin (50 g/mL), neomycin (100
g/mL), and amphotericin B (2.5 g/mL). The AM was
rinsed of blood and separated from the chorion by blunt
dissection. Then, the AMwas washed three times with PBS
and immersed in ice-cold PBS containing the antibiotics.
Preparation of AMCC. To prepare vascular con-
structs, the AM was wrapped around a sterile tube and
sutured longitudinally, so that the amniotic epithelium was
placed in the lumen side of the AMCC. The AMCCs were
4 cm long and the outside diameter was 8 mm. AMCCs
were immersed in PBS and stored at 4°C no longer than 4
hours to use for implantation. All procedures for prepara-
tion of AMCC were done in sterile conditions, and no
additive sterilization method was used for this propose.
AMCC implantation. The Shahid Beheshti Medical
University Institutional Research Ethics Committee ap-
proved all animal experiments. All animals received care in
compliance with the Guide for the Care and Use of Labora-
tory Animals (National Institutes of Health publication
85-23, revised 1985). Eight AMCCs were implanted as
jugular vein interposition grafts in juvenile lambs, aged 4 to
6 months (25 kg). All animals were fasted 24 hours
before surgery.
Anesthesia was induced with sodium thiopental (50
mg/animal) and maintained with 1.5% to 2.0% isoflurane
through a 6.0-mm endotracheal tube using a positive-
pressure ventilator and 100% oxygen. The left external
jugular vein was exposed through a longitudinal 10-cm
incision. The small collateral vessels were tied, heparin
sulfate (2500 units) was administered, and the proximal
and distal ends of the implantation site were clamped. The
external jugular vein was transected and an AMCC was
sutured with 5-0 Prolene (Ethicon, Somerville, NJ) in a montinuous running fashion. The vascular clamp was slowly
emoved and flow was resumed through the AMCC graft.
fter venous flow was confirmed by an empty-refill test
erformed several times, the incision was closed in layers
sing absorbable suture.
The sheep were recovered and monitored daily for
dverse effects. Doppler ultrasound imaging was per-
ormed at 5 and 48 weeks after grafting. The external
ugular veins on the opposite side of the neck were used
s the control to evaluate blood flow and Doppler ultra-
ound results. At the indicated times, animals were eu-
hanized using 10 mL concentrated sodium barbiturate.
MCC grafts were removed along with intact caudal and
ephalad native vessel. Tissue segments were processed
or histology and immunohistochemistry. For histologic
valuation, the grafts were harvested with native vein 1
m above and below the anastomosis, which was used as
he control in this study.
Histology. For histologic study, the grafts were cut
ongitudinally, and tissue samples were fixed in 4% parafor-
aldehyde in cacodylate buffer for at least 72 hours. Sam-
les were embedded in paraffin and 5-m sections were cut
nd stained with hematoxylin and eosin (H&E), following
outine procedures.
Scanning electron microscopy. Scanning electron
icroscopy (SEM) was used to further assess endothelial
orphology. Specimens for SEM were fixed in 4% parafor-
aldehyde for 24 hours. The fixed specimens were dehy-
rated in an alcohol gradient (40%, 60%, 80%, and 99.9%,
0 minutes each). Samples were critical point dried using a
ritical point drier CPD030 (BAL-TEC, Balzers, Liechten-
tein) and mounted on stubs for SEM. The mounted
amples were coated with gold using a sputter coating
evice SCD005 (BAL-TEC) and were analyzed using a
eiss DSM 940A SEM (Zeiss, Oberkochen, Germany).
Immunohistology. Paraffin-imbedded tissue samples
ere cleared by washing with xylene, followed by gradual
ashing with ethanol (100%, 80%, and 50%). Paraffin-free
ections were incubated in blocking buffer (PBS containing
.1% Triton-X-100 and 2% skim milk) for 1 hour. Slides
ere washed with PBS containing 0.1% Triton-X-100.
nti-von Willebrand factor (vWf) polyclonal antibody (1:
00;Abcam,Cambridge,Mass)was applied at 4°Covernight.
luorescein isothiocyanate-conjugated goat-antirabbit im-
unoglobulin G was used as a second antibody (1:1000,
nvitrogen, Carlsbad, Calif) at room temperature for 1
our. The sections were mounted and photographed
sing a fluorescent microscope.
ESULTS
AMCC implantation. In this study for the construc-
ion of the vein graft, the AM was rolled around a tube and
MCCs were interposed to external jugular vein by end-
o-end anastomosis in the sheep models (Fig 1, A). When
he clamps were removed after implantation, blood flow
esumed and AMCCs appeared perfectly integrated with
he original vein. There was no macroscopic sign of abnor-
al tube dilation or oozing of blood. In addition to the
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gations were performed after implantation at 5 weeks in
four sheep and 48 weeks in four sheep.
Macroscopic appearance. At 5 weeks after implanta-
tion, grafts were completely patent and displayed no
signs of dilation (Fig 2, A). The internal surface was
smooth and shiny, without any evidence of thrombus
formation. Anastomoses were smooth and not stenosed.
In one sheep, the caudal side of the anastomosis was
stenotic. After 48 weeks, grafts were still completely
patent and displayed no signs of neointimal hyperplasia,
dilation, or stenoses (Figs 1, B and 2, B). No fibrosis was
evident in grafts at 48 weeks. No signs of infection or
bacterial contamination were seen throughout the re-
peated testing of all animals.
Histology. H&E staining revealed a monolayer of
endothelial cells (Fig 3, A and B). No signs of inflamma-
tion, such as leukocyte infiltration or giant cells, were
observed in histology sections (Fig 3, B). Staining with
H&E confirmed that the implanted AMCCs were inte-
grated well with the native veins (Fig 3, C).
The lumen of each graft was analyzed with fluores-
cence microscopy and SEM to assess the morphology
and integrity of the endothelium. Ultrastructural assess-
ment of the AM before and after implantation provided
Fig 1. A, The amniotic membrane-constructed cond
end-to-end anastomosis in a sheep model. The black arr
respectively. B, The vascular graft is shown at 48 weeks
jugular vein and the white arrowhead designates the imp
Fig 2. Ultrasound imaging of the grafts at (A) 5 and
patent.more information about the morphologic qualities of the aells on the lumen side. SEM revealed that amniotic
pithelial cells were irregular polygonal or round in
hape (Fig 4, A). A confluent layer of cells with normal
ndothelial cell morphology was seen on the lumen side
f the entire AMCC at 48 weeks after implantation (Fig
, B). The endothelial cells were uniformly distributed
bout the lumen of AMCCs. All grafts exhibited a con-
uent surface, without a bare area. Grafts retained this
orphology up to 48 weeks (Fig 3, C). To confirm
ndothelial characteristic of these cells, immunohisto-
hemistry was done for vWf, a marker for endothelial
ells. A monolayer of vWf-positive cells was detected in
istology sections of the grafts (Fig 3, D).
ISCUSSION
Lack of availability of autologous vascular grafts and
he pain and discomfort associated with the donor site
ecessitate the development of tissue-engineered blood
essels for vascular regeneration. In this study, we used
he AM as a natural biomaterial for construction of a vein
raft. AMCCs were implanted in the jugular vein of 4- to
-month-old lambs and allowed to remain in vivo for up
o 48 weeks.
Recent studies have demonstrated that inflammatory
hanges, such as infiltration and activation of monocytes,
rafts were interposed to the external jugular vein by
d arrowhead indicate cephalad and caudal anastomoses,
implantation. The white arrows designate the external
amniotic membrane-constructed conduit.
8 weeks postoperatively indicated that the grafts wereuit g
ow an
after(B) 4re the main pathologic features at early and late stages of
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novel target for prevention of vein graft failure.8 In this
study, we observed no sign of inflammation in the mac-
roscopic or histologic investigations. This can be attrib-
uted to the anti-inflammatory and antimicrobial prop-
erty of the AM.
There are several reports of reduction of inflammation
Fig 3. Histologic and immunohistochemical staining of
and the (B) amniotic membrane-constructed conduit (A
eosin staining shows a monolayer of endothelial cells on
anastomotic site after 48 weeks stained with hematoxylin
vein. The black arrow points to the anastomotic site, a
respectively. D, Immunostaining of sections from sampl
endothelial cells characteristic of luminal surface of AM
staining of the same field. Scale bar: 50 m.
Fig 4. A, Scanning electron photomicrographs show th
are irregular polygonal or round in shape. B, The lum
contains cells with endothelial cells morphology that are c
luminal surface of grafts at 48 weeks postgrafting.with the AM. Expression of interleukin-1 and interleukin- e, highly potent proinflammatory cytokines, is markedly
uppressed by the AM stromal matrix.9 Moreover, natural
nhibitors of matrix metalloproteases (MMPs), which are ex-
ressed by infiltrating polymorphonuclear cells and macro-
hages, have been found in the AM.10,11 Amniotic epithelial
ells have the ability to produce -defensins, the major group
f antimicrobial peptides expressed at mucosal surfaces by
minal surface of (A) native vein 1 cm above anastomosis
) is shown at 5 weeks postoperatively. Hematoxylin and
luminal surface of AMCC. C, A longitudinal section of
osin showed that the graft integrated well with the native
e triangle and star indicate native vein and the graft,
ing antibodies against von Willebrand factor confirmed
he inset shows 4’,6-diamidino-2-phenylindole nuclear
amniotic epithelial cells of the fresh amniotic membrane
urface of the amniotic membrane-constructed conduit
ent and distributed uniformly, without bare areas, in thethe lu
MCC
the
and e
nd th
es us
CC. Tat the
inal s
onflupithelial cells.7
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teinase inhibitor and elafin, two low-molecular-mass elastase
inhibitors.7,12 In addition to their anti-inflammatory roles,
elafin and secretory leukocyte proteinase inhibitor have anti-
microbial actions and act as components of the innate immune
system to protect related surfaces from infection.13 The pres-
ence of lactoferrin and interleukin-1 receptor antagonist on
the AM are the other mechanisms for antimicrobial and anti-
inflammatory properties of the AM.14
Allogenic biomaterials used in transplantation are
prone to severe rejection, limiting their usefulness in
vascular grafts.15 In vascular allografts, for example, the
endothelial cells, in particular, are known to act as
antigen-presenting cells, leading to rejection.16 Al-
though in this study we did not use immunosuppressant
agents, no rejection reaction or stenosis was evident in
any graft. Low immunogenicity is an important property
that makes the AM a proper biomaterial in vein grafting.
The major factor that appears to prevent the rejection of
the AM is its expression of human leukocyte antigen
(HLA)-G. In contrast to HLA-A and HLA-B class I
genes that are downregulated in human AM, nonpoly-
morphic class I molecules, including HLA-G are ex-
pressed in amnion cells.9,17
Our findings showed that implanted AMCCs main-
tained a uniform endothelial monolayer that expressed
vWf, a marker for mature endothelial cells, and Doppler
ultrasound imaging at 5 and 48 weeks after grafting dem-
onstrated graft patency. Confluence in this study was de-
fined as complete endothelial cell coverage of the graft
lumen as seen on SEM. As mentioned, a major contribut-
ing factor to the high failure rate has been related to the
intrinsic thrombogenicity of the currently existing pros-
thetic materials. Creation of a confluent layer of endothelial
cells on the surface of biomaterials is an admitted solution
for the prevention of thrombus formation and results in
patency.2
One of the unsolved problems of this study is the
origin of endothelial cells, which is not clear from the
current results. There are two hypotheses for this ques-
tion. First, these are endothelial cells that originated
from the surrounding vascular bed and have migrated
from the adjacent vein or from circulating progenitor
cells. Removing the amniotic epithelial cells is a prereq-
uisite for this purpose, so that the basement membrane
of the AM would serve as a scaffold for attachment or
differentiation, or both, of endothelial or progenitor
cells. However, current methods used for removing the
amniotic epithelial cells are highly variable, and the
consequent effects on the structural and molecular com-
position of the basement membrane are ambiguous.
Therefore, we did not scrape the cells, and fresh AM
(with epithelial cells) was used as the implant in this
study. In the body, deletion of amniotic epithelial cells
can occur by apoptosis. It has been reported that in
intracorneal transplantation of the AM, amniotic epithe-
lial cells gradually disappeared. eAnother possibility is that some amniotic epithelial cells
re apoptotic cells and easily disappear under particular
onditions such as transplantation.18 Fas signaling or
MPsmay be important in apoptosis of amniotic epithelial
ells.19 On the basis of this hypothesis, after removal of the
mniotic epithelial cells, the basement membrane of the
M, which has rich extracellular matrix components such
s collagen, laminin, nidogen and fibronectin, serves as a
atural scaffold for the attachment of endothelial or pro-
enitor cells. It is clear that confluence and adherence of
ells substantially depend on the composition of the sub-
trate.20,21
We recently showed that the basement membrane of
he AM is a proper substrate for cultivation of endothelial
ells.6 However, whether amniotic epithelial cells are ap-
ptotic is a controversy that seems to be related to the
egion of the fetal membrane that was used for preparation
f the AM. The comprehensive mapping at term has
hown that an area of the AM exhibits unique morpho-
ogic features that are only found within a restricted area,
nder the title of “zone of altered morphology” (ZAM).
hese features include structural weakness and marked
isruption of the connective tissue layers and marked
eduction of the thickness and cellularity of the mem-
rane.21 Apoptosis of cells and degradation of basement
embrane by MMPs in ZAM are proposed mechanisms of
hese features.22 To avoid the ZAM in this study, only
embranes from elective Cesarean sections were used that
id not overly the lower uterine pole and cervix.
The second hypothesis is based on the differentiation of
mniotic epithelial cells into endothelial cells. Because the
ndothelial cells were confluent and uniform throughout
he length of the graft, without bare areas, they are likely
mniotic epithelial cells that differentiate to endothelial
ells. Recent studies aimed at defining the stem cell-like
haracteristics of amniotic epithelial cells show that these
ells express the surface markers associated with embryonic
tem cell, for example, stage-specific embryonic antigens-3
nd -4, and tumor rejection antigen-1-60 (TRA-1-60) and
RA-1-81. These cells also express pluripotent stem cell-
pecific transcription factors such as octamer-binding tran-
cription factor-4 and homeobox transcription factor
anog.23,24 Additional experiments demonstrated in vitro
ifferentiation of amniotic epithelial cells into the cells of
hree germ layers; in cardiac cells (mesodermal lineage),
euronal and glial cells (ectodermal lineage), and pancre-
tic and hepatic cells (endodermal lineage), all were positive
or specific markers.5,25,26
On the basis of these studies, apoptosis is not the fate of
mniotic epithelial cells, but these cells are clonogenic and
his cloning efficiency is comparable to some human em-
ryonic stem cells lines.27 To our knowledge, there is no
eport on the endothelial differentiation of amniotic epithe-
ial cells. Therefore, further investigations will be required
o determine the origin of endothelial cells. In addition,
xpressions of genes and proteins involved in graft remod-
ling and development, endothelial differentiation, release
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considered in future studies.
In one AMCC, we observed stenosis that may have
been related to mismatch in the diameter of the AMCC
and the vein or to the type of suture. Despite having
good mechanical properties, the AM is a thin layer and
presents technical limitations concerning suturing. A
new approach might include the use of glues as a substi-
tute for suturing.28
The AM has other advantages that make it one of the
most possible candidates for vascular transplantation.
The AM displays antifibroblastic activity in suppressing
transforming growth factor- and subsequent fibroblast
differentiation and, hence, inhibits postoperative fibro-
sis.29 The AM can also be easily obtained and has been
used for skin and ophthalmic transplantation with good
clinical results.
The promising results of the current study showed
that the AM might evolve into a clinically useful alterna-
tive for vascular surgery. To the best of our knowledge,
this is the first study to report information about the in
vivo application of AM as an implant in vascular surgery.
The mechanical properties of AM seem to be the most
important issue for using it as an implant in the arterial
circulation. We recently showed that the tensile strength
of fresh AM is enough to tolerate blood pressure6;
however, further in vivo experimental studies will be
required to confirm these data.
CONCLUSIONS
The present study showed that the AM could be a
proper candidate for vascular tissue engineering. We found
that conduits constructed from AM were patent for up to
48 weeks of implantation in the jugular vein, and no sign of
inflammation, infection, or stenosis was seen in the grafts. A
confluent layer of endothelial cells was observed on the
lumen side of grafts, whose origin remains to be elucidated
in the future studies.
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